Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Honeywell €1.15 billion senior notes offering
The investment-grade notes are due 2027 and 2032
Honeywell $1.75 billion senior notes offering
The investment-grade notes are due 2029 and 2034
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
Weyerhaeuser $750 million notes offering
The investment-grade notes are due 2026
Bloom Energy $632.5 million green convertible notes and capped call transactions
The 3% green convertible senior notes are due 2028
Mirion Technologies $52.9 million secondary offering
The shares are listed on the NYSE
Corteva $1.2 billion senior notes offering
The investment-grade notes are due 2026 and 2033
Schlumberger $1 billion senior notes offering
The investment-grade notes are due 2028 and 2033
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market